Tilray® Receives Approval from U.S. Government to Import a Medical Cannabis Study Drug for a Clinical Trial at the University of California San Diego Center for Medicinal Cannabis Research
“Tilray is proud to support this crucial research,” says Dr.
Essential Tremor is a neurological movement disorder characterized by involuntary and rhythmic shaking. ET has extremely high prevalence rates; 0.4% of the general population suffer from ET, and that figure rises to 4.6%-6.3% among those 65 and older. Essential Tremor can have a significant impact on a patient’s quality of life, causing embarrassment, social withdrawal, disability, and loss of occupation. Many patients do not experience relief with the current drugs on the market or find the side-effects of these drugs to be unbearable.
Additional Quotes:
- “It’s exciting to advance our work in this area by conducting a first-of-its kind trial of purified medicinal cannabis for a common neurological disorder like essential tremor,” says Dr. Nahab. “Until now patients have been on their own to figure out the efficacy, safety, and dosing of cannabinoids. This trial should help answer many of these critical questions.”
-
“We are extremely enthusiastic about the initiation of this study,
extending as it does CMCR’s program to discover therapeutic potential
of various cannabinoid preparations,” said Dr.
Igor Grant ,Center for Medicinal Cannabis Research Director. “These studies are promising to uncover new treatments for difficult to treat conditions.” -
“The IETF is proud to provide grant funding for this study which
provides hope to the essential tremor community,” said
Patrick McCartney , executive director of theInternational Essential Tremor Foundation . “The effectiveness of cannabis as a treatment for essential tremor has long been a topic of interest in the ET community. We are grateful to Dr. Nahab andUC San Diego Center for Medicinal Cannabis Research for their dedication to scientific research of this kind. And we commendTilray for the development of this study drug which has the potential to help thousands of people who struggle with ET.”
About Tilray®
Tilray is a global pioneer in the research, cultivation, production and distribution of cannabis and cannabinoids currently serving tens of thousands of patients in eleven countries spanning five continents.
About the Center of
Established in 2000, the
About
Headquartered in
Cautionary Note Regarding Forward-looking Statements
This press release contains “forward-looking statements” within the
meaning of the U.S. Private Securities Litigation Reform Act of 1995 and
“forward-looking information” within the meaning of Canadian securities
laws, or collectively, forward-looking statements. Forward-looking
statements in this press release may be identified by the use of words
such as, “may”, “would”, “could”, “will”, “likely”, “expect”,
“anticipate”, “believe, “intend”, “plan”, “forecast”, “project”,
“estimate”, “outlook” and other similar expressions, including
statements in respect to Tilray’s intention to import cannabis products
for research purposes. Forward-looking statements are not a guarantee of
future performance and are based upon a number of estimates and
assumptions of management in light of management’s experience and
perception of trends, current conditions and expected developments, as
well as other factors that management believes to be relevant and
reasonable in the circumstances, including assumptions in respect of
current and future market conditions, the current and future regulatory
environment and future approvals and permits. Actual results,
performance or achievement could differ materially from that expressed
in, or implied by, any forward-looking statements in this press release,
and, accordingly, you should not place undue reliance on any such
forward-looking statements and they are not guarantees of future
results. Forward-looking statements involve significant risks, including
the risks discussed under the caption “Risk Factors” in
View source version on businesswire.com: https://www.businesswire.com/news/home/20180918005163/en/
Source:
Tilray Media:
Chrissy Roebuck, +1-416-560-5712
chrissy.roebuck@tilray.com
or
Tilray
Investors:
Katie Turner, +1-646-277-1228
Katie.turner@icrinc.com